keyword
MENU ▼
Read by QxMD icon Read
search

RG7090

keyword
https://www.readbyqxmd.com/read/26219727/basimglurant-for-treatment-of-major-depressive-disorder-a-novel-negative-allosteric-modulator-of-metabotropic-glutamate-receptor-5
#1
Kjell Fuxe, Dasiel O Borroto-Escuela
INTRODUCTION: Metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators (NAM) such as 2-Methyl-6-(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP) can produce antidepressant-like effects; an example being the forced swim test in rodents. It is therefore of high interest that a new mGlu5 NAM called basimglurant (RO4917523, RG7090) was recently introduced for clinical development in depression. AREAS COVERED: The current article reports on the preclinical and clinical work with basimglurant which strongly supports its use for treatment of depression...
2015: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/25665805/pharmacology-of-basimglurant-ro4917523-rg7090-a-unique-metabotropic-glutamate-receptor-5-negative-allosteric-modulator-in-clinical-development-for-depression
#2
Lothar Lindemann, Richard H Porter, Sebastian H Scharf, Basil Kuennecke, Andreas Bruns, Markus von Kienlin, Anthony C Harrison, Axel Paehler, Christoph Funk, Andreas Gloge, Manfred Schneider, Neil J Parrott, Liudmila Polonchuk, Urs Niederhauser, Stephen R Morairty, Thomas S Kilduff, Eric Vieira, Sabine Kolczewski, Juergen Wichmann, Thomas Hartung, Michael Honer, Edilio Borroni, Jean-Luc Moreau, Eric Prinssen, Will Spooren, Joseph G Wettstein, Georg Jaeschke
Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is currently limited to modulators of monoamine neurotransmitters and second-generation antipsychotics. Recently, glutamatergic approaches for the treatment of MDD have increasingly received attention, and preclinical research suggests that metabotropic glutamate receptor 5 (mGlu5) inhibitors have antidepressant-like properties. Basimglurant (2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine) is a novel mGlu5 negative allosteric modulator currently in phase 2 clinical development for MDD and fragile X syndrome...
April 2015: Journal of Pharmacology and Experimental Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"